Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists.

Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC.

Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. doi: 10.1016/j.ejphar.2008.12.044. Epub 2009 Jan 11.

PMID:
19168056
2.

Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.

Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, Middlemiss DN.

Br J Pharmacol. 1999 Apr;126(7):1620-4.

3.

Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.

Davis CN, Bradley SR, Schiffer HH, Friberg M, Koch K, Tolf BR, Bonhaus DW, Lameh J.

BMC Pharmacol. 2009 Dec 2;9:14. doi: 10.1186/1471-2210-9-14.

5.

Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.

Messer WS Jr, Abuh YF, Liu Y, Periyasamy S, Ngur DO, Edgar MA, El-Assadi AA, Sbeih S, Dunbar PG, Roknich S, Rho T, Fang Z, Ojo B, Zhang H, Huzl JJ 3rd, Nagy PI.

J Med Chem. 1997 Apr 11;40(8):1230-46.

PMID:
9111297
6.

AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.

Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14.

PMID:
19835892
7.

G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists.

Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RA.

J Pharmacol Exp Ther. 2008 Nov;327(2):365-74. doi: 10.1124/jpet.108.141788. Epub 2008 Jul 29.

8.

Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.

De Lorme KC, Grant MK, Noetzel MJ, Polson SB, El-Fakahany EE.

J Pharmacol Exp Ther. 2007 Dec;323(3):868-76. Epub 2007 Sep 12.

9.
10.

Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice.

Gautam D, Heard TS, Cui Y, Miller G, Bloodworth L, Wess J.

Mol Pharmacol. 2004 Aug;66(2):260-7.

11.

Dioxane and oxathiane nuclei: suitable substructures for muscarinic agonists.

Piergentili A, Quaglia W, Giannella M, Del Bello F, Bruni B, Buccioni M, Carrieri A, Ciattini S.

Bioorg Med Chem. 2007 Jan 15;15(2):886-96. Epub 2006 Oct 21.

PMID:
17084634
12.

Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.

Messer WS Jr, Rajeswaran WG, Cao Y, Zhang HJ, el-Assadi AA, Dockery C, Liske J, O'Brien J, Williams FE, Huang XP, Wroblewski ME, Nagy PI, Peseckis SM.

Pharm Acta Helv. 2000 Mar;74(2-3):135-40.

PMID:
10812950
13.
14.

Structure-activity relationships in 2,2-diphenyl-2-ethylthioacetic acid esters: unexpected agonistic activity in a series of muscarinic antagonists.

Scapecchi S, Marucci G, Matucci R, Angeli P, Bellucci C, Buccioni M, Dei S, Gualtieri F, Manetti D, Romanelli MN, Teodori E.

Bioorg Med Chem. 2001 May;9(5):1165-74.

PMID:
11377175
15.

Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.

Thomas RL, Langmead CJ, Wood MD, Challiss RA.

J Pharmacol Exp Ther. 2009 Dec;331(3):1086-95. doi: 10.1124/jpet.109.160242. Epub 2009 Sep 18.

16.
17.

Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine.

Terry AV Jr, Buccafusco JJ, Borsini F, Leusch A.

Psychopharmacology (Berl). 2002 Jul;162(3):292-300. Epub 2002 May 29.

PMID:
12122487
18.

Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.

McArthur RA, Gray J, Schreiber R.

Curr Opin Investig Drugs. 2010 Jul;11(7):740-60. Review.

PMID:
20571970
19.

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

Mirza NR, Peters D, Sparks RG.

CNS Drug Rev. 2003 Summer;9(2):159-86. Review.

20.

Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.

Watt ML, Schober DA, Hitchcock S, Liu B, Chesterfield AK, McKinzie D, Felder CC.

J Pharmacol Exp Ther. 2011 Aug;338(2):622-32. doi: 10.1124/jpet.111.182063. Epub 2011 May 10.

Supplemental Content

Support Center